Smart targeting of EGFR in lung cancer

Stephanie Kermorgant Jonna Nevo amp; Johanna Ivaska

首页> 外文期刊>Pharmacogenomics >Smart targeting of EGFR in lung cancer

【24h】

Smart targeting of EGFR in lung cancer

机译：EGFR在肺癌中的靶向作用

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In 2004, the WHO estimated that lung cancer causes 1.3 million deaths per year, thus being the leading cause for cancer mortality. Non-small-cell lung cancer (NSCLC), which encompasses the majority (80%) of different lung cancer subgroups, is usually diagnosed with locally advanced or inct.istatic disease when surgery is no longer feasible. In addition to chemotherapy and radiotherapy! different molecular targeted therapies against EGF receptor (EGFR) and VEGF are combined in the clinical use.

机译：在2004年，WHO估计肺癌每年导致130万人死亡，因此是导致癌症死亡的主要原因。非小细胞肺癌（NSCLC）涵盖了大多数（80％）不同的肺癌亚组，通常在手术不再可行时被诊断为局部晚期或静息性疾病。除了化学疗法和放射疗法！针对临床应用，针对EGF受体（EGFR）和VEGF的不同分子靶向疗法相结合。

著录项

来源
《Pharmacogenomics》 |2010年第6期|共2页
作者
Stephanie Kermorgant Jonna Nevo amp; Johanna Ivaska;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Smart targeting of EGFR in lung cancer [J] . Stephanie Kermorgant Jonna Nevo amp, Johanna Ivaska Pharmacogenomics . 2010,第6期

机译：EGFR在肺癌中的靶向作用
2. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer [J] . Kim Ye-Jin, Baek Du-San, Lee Seyoung, Cancer letters . 2019,第期

机译：EGFR和Neuropilin-1的双靶向抑制KRAS-突变体非小细胞肺癌的EGFR靶向抗体治疗的抗性
3. SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals [J] . Kelin She, Shenghua Fang, Wei Du, Cancer Cell International . 2019,第1期

机译：通过重新激活EGFR / PI3K / AKT信号，EGFR靶向肺癌的肺癌治疗需要SCD1
4. Development of EGFR-Targeting Nanomedicine for Effectively and Noninvasively Treats Lung Cancer Patients by Aerosol Delivery [C] . Ching-Li Tseng, Yueh-Hsiu Wu, Su-Wen Yu, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：EGFR靶向纳米药物的开发，可通过气雾剂有效无创地治疗肺癌患者
5. Application of Quantitative Metrics for EGFR-Targeted Non-Small Cell Lung Cancer Therapy Using [11C]Erlotinib PET. [D] . Petrulli, Joseph Ryan. 2017

机译：定量指标在EGFR靶向非小细胞肺癌治疗中的应用[11C]厄洛替尼PET。
6. Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR? [O] . Jacques De Greve, Philippe Giron 2020

机译：在肺癌中靶向酪氨酸激酶抑制剂耐药的突变EGFR通路而不靶向EGFR？
7. Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers [O] . Sebastian Mondaca, Michael Offin, Laetitia Borsu, 2019

机译：从常规的常规评估常规评估EGFR突变体肺癌患者EGFR T790M电阻突变的常规评估
8. Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR Mutant and ALK Positive Lung Cancers. [R] . Sequist, L., Engelman, J. 2016

机译：缺乏BIm表达作为EGFR突变体和aLK阳性肺癌中靶向治疗的内在和获得性抗性的机制。

Smart targeting of EGFR in lung cancer

摘要

著录项

相似文献

相关主题

期刊订阅